English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Women and members of some minority groups are more likely than other Americans to have a stroke. Minorities are often more likely to have other neurologic diseases. This makes it important for women and minorities to take part in research that tests new drugs for stroke or other neurologic diseases. If there are not enough women and minorities in these drug studies, we will not know whether or not the study results can be applied to them. We also will not be able to decide whether the effects of the drug are the same in women and minorities as they are in other participants. In the past, the number of women and minorities taking part in drug studies has been very low. This has been changing recently, but in many drug studies, their participation is still too low. In their article in this issue of Neurology ® (2011;76:354–360), Dr. Burke and his colleagues report how much progress has been made in involving women and certain minority groups in drug studies for neurologic conditions.Dr. Burke and his colleagues looked at participation by women, African Americans, and Hispanic Americans in the major drug studies funded by the National Institute of Neurological Disorders and Stroke (NINDS). The NINDS is the main source of federal funding for drug studies in neurologic diseases. They looked at all major studies completed between January 1977 and October 2009. They wanted to see whether reports about the studies mentioned how many women and minorities took part, and whether enough women and minorities were included. To see if there was change over time, they compared the studies …

Do enough women and minorities take part in drug studies for neurologic diseases?